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Abstract Introduction Patients with chronic liver disease
ultimately progress to develop cirrhosis and portal hyper-
tension. Recently it seems well established that nitric oxide
disturbances play a key role in the pathogenesis of chronic
liver disease and portal hypertension. The aim of this work
was to clarify the correlation between chronic liver disease
stages, liver function status, esophageal varices presence
and nitric oxide disturbances. Subjects and methods All
subjects (n = 120) in the present study were classiﬁed into;
group I which included 15 age and sex matched healthy
volunteers (taken as control), group II which included 20
patients with chronic active hepatitis, and group III which
included 85 patients with hepatic cirrhosis. All subjects
included were subjected to full clinical assessment, routine
laboratory investigations, serum nitrate level determination
using colorimetric method, abdominal ultrasonography and
upper endoscopy. Results Increased serum nitrate level
could not be detected in patients with chronic active hep-
atitis as well as those with early cirrhosis (Child’s class A).
Progressive and signiﬁcant increase of serum nitrate levels
were detected in more advanced stages of cirrhosis (Child’s
class B & C). The best non-invasive predictor for the
presence of oesophageal varices was a combination of
platelet count \150.000/mm
3, splenomegaly [18 cm,
Child’s class B or C and serum nitrate C38 lmol/l, with
93.3% sensitivity and 100% speciﬁcity. Conclusion Serum
nitrate level can be used as a non-invasive predictor for
progression of chronic liver disease as well as for the
presence of oesophageal varices.
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Introduction
Chronic active hepatitis and cirrhosis are classiﬁed as
chronic liver diseases. Chronic liver diseases may be
accompanied by portal hypertension. Liver cirrhosis with
portal hypertension is characterized by several systemic
and splanchnic hemodynamic changes [1]. Within the
splanchnic and systemic circulation, there is increased
cardiac output and hyperdynamic circulation that contrib-
ute to increased ﬂow into the portal circulation, thereby
perpetuating portal hypertension [2]. Vascular remodeling
and angiogenesis occur at the portosystemic interface so as
to relieve the resulting excess portal pressure and allow
decompression by redistributing ﬂow through esophageal
collaterals. Unfortunately, the resulting generation of var-
ices is a major contributor to morbidity and mortality [2].
Increased serum nitric oxide (NO) levels in patients with
cirrhosis have been reported repeatedly [3, 4]. A previous
Egyptian study indicated an association between the NO
levels and the development and progression of liver cir-
rhosis [5]. NO system disturbances seem to play a key role
in the pathogenesis of chronic liver disease and are pro-
posed as one of the major endogenous vasodilators in
portal hypertension [6, 7]. It is also thought to be the cause
of some complications associated with end-stage liver
disease [8].
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DOI 10.1007/s12072-008-9077-yThe aim of this work was to clarify the correlation
between liver disease stages, liver function status, oesoph-
ageal varices (OV) extent, and the serum nitrate levels.
Patients and methods
This study was conducted between August 2005 and
August 2006 in Al-Azhar University Hospital. One hun-
dred and twenty persons (90 men and 30 women) were
included and classiﬁed into 3 groups. Group I, which
included 15 (10 men and 5 women) age- and sex-matched
volunteers was taken as controls. Their age ranged from 30
to 59 years. Group II included 20 (13 men and 7 women)
patients with chronic active hepatitis. Their age ranged
from 32 to 56 years. Group III included 85 (67 men and 18
women) patients with hepatic cirrhosis. Their age ranged
from 31 to 60 years. Cirrhotic patients (group III) were
subdivided into A (n = 25), B (n = 30), and C (n = 30)
according to Child’s classiﬁcation.
Chronic active hepatitis and cirrhosis were diagnosed by
clinical, biochemical, ultrasound, and/or histological crite-
ria. The causes of chronic liver disease in our patients were
attributed to HCV (n = 64), HBV (n = 46), and both HCV
and HBV (n = 10). The patients were not under speciﬁc
treatment for their liver diseases or vasoactive drugs during
the study. Patients with hepatosplenic schistosomiasis,
hepatocellular carcinoma, portal vein thrombosis, cardiac
failure, renal failure, respiratory failure, and other chronic
diseases, patients consuming relevant amounts of alcohol,
and pregnant women were excluded from the study. Patients
with excess dietary nitrite/nitrate intake were excluded, and
standardized diet was not used.
Standard commercial photometric assays for alanine
aminotransferase, aspartate aminotransferase, serum bili-
rubin, serum albumin, prothrombin time, and INR were
performed in all persons (n = 120). Diagnosis of both
HBV and HCV was based on HBsAg, HBcAb, and
HCVAb tests by ELISA technique using DiaSorin kits
(Italy). For serum nitrate testing, fasting blood samples
were taken from both patients and control groups at 9 a.m.
Venous samples were collected in a serum separator tube,
and then centrifuged; ﬁnally, serum was removed and
stored at -20C or below until it was analyzed. All sam-
ples were diluted at least 2-fold into reduction buffer. After
dilution, samples were subjected to ultraﬁltration through a
10,000-molecular weight cutoff ﬁlter to remove high
molecular weight proteins. NO metabolites were measured
by using BLOXYTECH nitric oxide assay (colorimetric
assay). The resulting values were given as lmol/l nitrate
(normal nitrate value = 0-30 lmol/l).
For hepatic and splenic span measurements, hepatic
texture evaluation, portal and hepatic venous systems
assessment, and detection of ascites, all patients (n = 120)
were subjected to abdominal ultrasonography. According
to the longitudinal axis of the spleen, splenomegaly may be
of the following types: mild (13-15 cm), moderate (16–
18 cm), and massive ([18 cm). In the presence of ascites,
it is graded as mild, moderate, and marked on basis of
ultrasonography.
For detection and grading of OV, all persons were
subjected to upper endoscopy. All endoscopies were per-
formed in a single endoscopy unit using a video endoscope,
and OV were classiﬁed according to the same criteria. OV
were classiﬁed using the small and large classiﬁcation,
where small OV are deﬁned as varices that ﬂatten with
insufﬂation or minimally protrude into the oesophageal
lumen, whereas large OV were deﬁned as varices that
protrude into the oesophageal lumen and touch each other
or ﬁll at least 50% of the oesophageal lumen.
Patients with chronic liver disease and compensated
liver function (n = 45) were subjected to percutaneous
transthoracic ultrasound-guided liver biopsies for the sep-
aration of chronic active hepatitis and Child’s class ‘‘A’’
cirrhosis.
The statistical analysis of data was performed using
SPSS software statistical computer package, Version 10.
Comparison between the groups was made with the Student
t test for unpaired data. Analysis of variance was performed
to test the statistical signiﬁcant difference between more
than 2 means. All results were expressed as mean ± SD.
Correlation coefﬁcient r was measured to test a positive or
a negative linear relation between 2 variables. Chi-square
analysis was performed as a test of signiﬁcance. Result was
considered signiﬁcant if P\0.05 and highly signiﬁcant if
P\0.01.
Results
No signiﬁcant difference was reported among all groups
either in age or in sex distribution (P[0.05). Patients with
advanced liver disease (Child’s class B or C) were signif-
icantly hypotensive and had higher heartrate (P\0.01).
There was no signiﬁcant correlation between nitrate levels
and age or sex distributions (P[0.05). In contrast, a
highly signiﬁcant positive correlation was reported
between serum nitrate levels and pulse rate (r = 0.36),
jaundice (r = 0.38), hepatic encephalopathy (r = 0.69),
and lower limb edema (r = 0.62) (P\0.01). Also, a
highly signiﬁcant negative correlation was found with
mean arterial blood pressure (r =- 0.42) (P\0.01). The
correlation between serum nitrate levels and the laboratory
investigations in the studied groups revealed a highly sig-
niﬁcant negative correlation with white blood cells count
(r =- 0.47), hemoglobin concentration (r =- 0.6), and
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123platelet count (r =- 0.63) (P\0.01). Although a highly
signiﬁcant negative correlation was found between serum
nitrate levels and serum albumin (r =- 0.72) (P\0.01), a
highly signiﬁcant positive correlation was reported with
serum bilirubin (r = 0.58) and INR values (r = 0.6)
(P\0.01). The difference between serum nitrate levels in
HCV and HBV chronic liver disease patients was statisti-
cally insigniﬁcant.
A highly signiﬁcant positive correlation was found for
serum nitrate levels with spleen size (r = 0.67) and ascites
grade (r = 0.77) (P\0.01). A highly signiﬁcant positive
correlation was observed between serum nitrate levels and
necroinﬂammatory grades (r = 0.48) (P\0.01) and
ﬁbrosis stages (r = 0.6) (P\0.01).
In comparison to the control group, patients with
chronic active hepatitis had no signiﬁcant increase in serum
nitrate levels (P = 0.711). In comparison to the control
group and patients with chronic active hepatitis, Child’s
class ‘‘A’’ patients had no signiﬁcant increase in serum
nitrate levels. In Child’s class ‘‘B’’ patients, a highly sig-
niﬁcant increase in serum nitrate levels was observed
compared with Child’s class ‘‘A’’ patients (P\0.001). In
addition, a highly signiﬁcant increase in serum nitrate
levels was observed in Child’s class ‘‘C’’ patients
compared with Child’s class ‘‘B’’ patients (P\0.001)
(Table 1).
A highly signiﬁcant difference was found between
serum nitrate levels in cirrhotic patients without OV and
those with small OV (P\0.01). Also, a highly signiﬁcant
increase in serum nitrate levels was found in cirrhotic
patients with large OV compared with cirrhotic patients
without OV (P\0.01) (Table 2). Comparing the serum
nitrate levels among different grades of OV in the same
Child’s class, a highly signiﬁcant positive correlation was
found between serum nitrate levels and OV grades
(Table 3).
The lower cutoff level of serum nitrate below which
large OV could not be detected in cirrhotic patients was
73 lmol/l. The best cutoff level of serum nitrate for pre-
diction of OV in cirrhotic patients was 38 lmol/l. It had
86.5% sensitivity, 83.3% speciﬁcity, 95% positive predic-
tive value, and 62.5% negative predictive value. Different
combinations of clinical, laboratory, and sonographic
variables were suggested to improve the performance of
serum nitrate level (C38 lmol/L) in the prediction of OV.
The best predictive formula was a combination of platelet
count\150,000/mm
3, splenomegaly[18 cm, Child’s class
B or C, and serum nitrate level C38 lmol/L, which had the
highest sensitivity (93.3%) and speciﬁcity (100%)
(Table 4).
Discussion
An increased serum nitrate level because of a metabolite of
NO was demonstrated in patients with chronic liver dis-
eases [9]. Also the level of nitrate could be correlated with
Child-Pugh classes in cirrhotic patients [10]. Previous
studies [9, 11] reported higher nitrate concentration in
patients with chronic hepatitis. We did not ﬁnd any sig-
niﬁcant difference between nitrate levels in patients with
chronic active hepatitis and healthy controls. This was
consistent with Parvu et al. [10] and Arkenau et al. [4]. A
possible explanation is that the differences in the severity
of inﬂammation and ﬁbrosis may cause varying serum
nitrate levels, and the etiology of chronic hepatitis may
explain the discrepancy between some previously reported
studies and our results. Cirrhosis is considered as the most
advanced stage of chronic liver disease. In viral cirrhosis,
there is a signiﬁcant increase in the serum nitrate [12–15].
In our study, the nitrate concentration was signiﬁcantly
increased in advanced degrees of cirrhosis (B and C). Also
nitrate level was correlated with Child’s classes.
Several complications are related to liver cirrhosis,
including the development of variceal hemorrhage. Vari-
ceal hemorrhage is a consequence of portal hypertension
that develops in cirrhosis both because of an increase in
splanchnic blood ﬂow secondary to vasodilatation within
the splanchnic vascular bed and because of increased
resistance to the passage of blood through the liver. NO
may play a critical role by promoting both collateral ﬂow
through dilatation of pre-existing vessels and vascular
remodeling and angiogenesis [16–18]. In advanced cir-
rhosis, nitrate levels can be correlated to complications of
portal hypertension [4, 9, 19–22]. Arkenau et al. [4]
established the connection between the extent of portal
hypertension and nitrate levels, whereas the progression of
OV was associated with higher circulating nitrate levels.
According to our results, higher nitrate levels were
observed in cirrhotic patients with OV. Also, good corre-
lations were found between nitrate levels in cirrhotic
patients and OV grades.
Table 1 Mean values of serum nitrate level in chronic liver disease
patients in comparison with control
Group Number Mean nitrate ± SD tP
Control 15 34.44 ± 3.17
CAH 20 34.15 ± 1.39 0.37 0.7119
Child’s A 25 35.74 ± 12.18 0.40 0.6890
Child’s B 30 57.05 ± 22.01 3.94 \0.01*
Child’s C 30 89.25 ± 22.21 9.46 \0.001*
CAH = Chronic active hepatitis, * highly signiﬁcant result
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123Taking into account these results, we examined the
value of nitrate levels as a noninvasive screening tool for
the presence of OV in cirrhotic patients. The noninvasive
assessment of the presence/absence of OV implies a series
of medical and social issues [23]. In fact, from a medical
point of view, such a noninvasive approach has to fulﬁll
some well-deﬁned characteristics that allow us to identify
patients with OV and enable us to concentrate on those
who are most likely to have OV. In particular, the accuracy
of such noninvasive approach must represent the best
compromise between the risk of missing an important
diagnosis, such as OV, and lack of clinical usefulness
because of the low speciﬁcity of the screening tool [28].
More accurately, such parameters should be directly related
to the pathomechanisms of OV, have lower cutoff levels
below which the presence of OV could be excluded, and
have good correlation with different OV grades.
Platelet count, spleen size, and Child’s class were the
most frequently explored noninvasive parameters in the
previous studies [24–28]. Although such parameters
showed good sensitivity and speciﬁcity, 2 problems are
encountered. On one hand, it has no cutoff value below
which the presence of OV should be excluded. On the other
hand, none of these parameters are directly related to the
pathomechanisms of OV; instead all of them are compli-
cations of portal hypertension and liver dysfunction that
can precede, follow, or occur simultaneously with OV.
Two recent studies [28, 29] addressed the ﬁrst problem
through expressing the platelet/spleen size and right liver
lobe/albumin ratios that can accurately determine the
presence of OV. Here we report a parameter directly
related to the pathomechanisms of OV, has a lower cutoff
level below which the presence of OV could be excluded,
and has good correlation with different OV grades. Ele-
vated serum nitrate level predicts OV in cirrhotic patients
with reasonable sensitivity and speciﬁcity, as well as it has
positive correlation with OV grades. The addition of low
platelet count, splenomegaly, and advanced Child’s classes
Table 2 Mean values of serum
nitrate levels in relation to
oesophageal varices grades
* Highly signiﬁcant result
Oesophageal varices grade Number of
patients (n = 85)
Mean nitrate ± SD t P ANOVA P
No oesophageal varices 10 36.6 ± 7.85 – – 478.16 \0.001*
Small oesophageal varices 43 51.04 ± 11.5 4.43 \0.001*
Large oesophageal varices 32 109.25 ± 3.54 28.72 \0.001*
Table 3 Mean values of nitrate levels in cirrhotic patients in relation to Child’s classes and oesophageal varices grades
Oesophageal varices grades Child class A Child class B Child class C
Number Mean nitrate
(lmol/l) ± SD
Number Mean nitrate
(lmol/l) ± SD
Number Mean nitrate
(lmol/l) ± SD
No oesophageal varices 7 30.17 ± 0.66 3 35.93 ± 2.96 0 0
Small oesophageal varices 16 39.8 ± 1.31 18 52.53 ± 2.12 9 68.8 ± 1.23
Large oesophageal varices 2 74.1 ± 1.56 9 104.67 ± 2.6 21 110.96 ± 1.89
ANOVA 29.99 65.15 102.62
P \0.001* \0.001* \0.001*
* Highly signiﬁcant result
Table 4 Noninvasive Predictors of oesophageal varices in cirrhotic patients
Noninvasive predictors Sensitivity
(%)
Speciﬁcity
(%)
PVP
(%)
PVN
(%)
Platelet count\150.000/mm
3 60.5 88.4 70 87
Platelet count\150.000/mm
3 + nitrate level C38 lmol/l 65.2 89.1 74 95
Platelet count\150.000/mm
3 + splenomegaly[18 cm 72.9 94.3 83 81.1
Platelet count\150.000/mm
3 + nitrate level C38 lmol/l + splenomegaly[18 cm 74.1 95.1 87.2 86
Platelet count\150.000/mm
3 + splenomegaly[18 cm + Child’s class B/C 85.1 100 100 93.9
Nitrate level C38 lmol/l 86.5 83.3 95.8 62.5
Platelet count\150.000/mm
3 + nitrate level C38 lmol/l + splenomegaly[18 cm + Child’s
class B/C
93.3 100 100 94.2
Predictive value positive = PVP, Predictive value negative = PVN
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123signiﬁcantly improve the serum nitrate sensitivity (93.3%)
for prediction of OV.
Conclusion
Serum nitrate levels can be used as a noninvasive predictor
for progression of chronic liver diseases and the presence
of OV. A large number of study subjects are needed for
further validation of these results.
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